MetaCap

Tempus AI Inc. Class A Company Profile

NASDAQ: TEMTechnologyComputer Software: Programming Data ProcessingUSD

54.04-5.57 (-9.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Tempus AI at a glance

Tempus AI Inc. Class A (NASDAQ: TEM) is a Computer Software: Programming Data Processing company in the Technology sector headquartered in Chicago, IL. Tempus AI is led by Mr. Eric P. Lefkofsky J.D. and employs about 3,800 people. The company's shares have traded publicly since 2024.

At a market capitalization of $9.86 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001717115, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Tempus AI do?

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Business description based on the company's public filings.

Company information

Legal name
Tempus AI Inc. Class A
Ticker
NASDAQ: TEM
Industry
Computer Software: Programming Data Processing
CEO
Mr. Eric P. Lefkofsky J.D.
Employees
3,800
Headquarters
600 West Chicago Avenue, Chicago, IL, United States
Phone
800 976 5448
Website
tempus.com
IPO year
2024
SEC CIK
0001717115

Companies similar to Tempus AI

TEM peer companies
CompanyPrice% ChgMarket capCompare
PINSPinterest Inc. Class A16.33-3.32%$9.37Bvs TEM
MTCHMatch Group Inc.39.13-0.03%$8.90Bvs TEM
FDSFactSet Research Systems Inc.311.93+1.28%$11.00Bvs TEM
FLUTFlutter Entertainment plc67.19-1.80%$11.68Bvs TEM
DOCNDigitalOcean Holdings Inc.66.76-13.40%$7.88Bvs TEM
SNAPSnap Inc. Class A4.55-11.13%$7.86Bvs TEM
TTDThe Trade Desk Inc. Class A13.38-8.10%$6.33Bvs TEM
BZKANZHUN LIMITED American Depository Shares12.87-1.98%$5.63Bvs TEM

Related